1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Estramustine Phosphate Sodium Capsules
Trade Name: EMCYT; ESTRACYT
Chemical Family: Nitrogen Mustard

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Antineoplastic

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B
Carcinogenicity: Category 2

EU Classification:

EU Indication of danger: Toxic to reproduction, Category 2
Carcinogenic: Category 3

EU Risk Phrases:

R40 - Limited evidence of a carcinogenic effect
R61 - May cause harm to the unborn child.
R62 - Possible risk of impaired fertility.

Label Elements

Signal Word: Danger
Hazard Statements:
H351 - Suspected of causing cancer
H360Df - May damage the unborn child. Suspected of damaging fertility

Precautionary Statements:
P202 - Do not handle until all safety precautions have been read and understood
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations
### 3. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estramustine Phosphate Sodium</td>
<td>52205-73-9</td>
<td>257-735-7</td>
<td>Repr.Cat.2;R61</td>
<td>Repr.1B (H360Df)</td>
<td>68</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Repr.Cat. 3;R62</td>
<td>Carc.2 (H351)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cat.3;R40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Silicon dioxide, colloidal NF</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Talc (non-asbestiform)</td>
<td>14807-96-6</td>
<td>238-877-9</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
<tr>
<td>Sodium lauryl sulfate</td>
<td>151-21-3</td>
<td>205-788-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td></td>
</tr>
</tbody>
</table>

**Additional Information:**

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion: Formation of toxic gases is possible during heating or fire.

Products:

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Estramustine Phosphate Sodium
Pfizer OEL TWA-8 Hr:

2 μg/m³

Silicon dioxide, colloidal NF
Australia TWA
2 mg/m³
Austria OEL - MAKs
4 mg/m³
0.3 mg/m³
Czech Republic OEL - TWA
0.1 mg/m³
4.0 mg/m³
Estonia OEL - TWA
2 mg/m³
Finland OEL - TWA
5 mg/m³
Germany - TRGS 900 - TWAs
4 mg/m³
Germany (DFG) - MAK
4 mg/m³
Ireland OEL - TWAs
6 mg/m³
2.4 mg/m³
Latvia OEL - TWA
1 mg/m³
OSHA - Final PELs - Table Z-3 Mineral D:

20 mppcf
Listed
Slovakia OEL - TWA
4.0 mg/m³
Switzerland OEL - TWAs
4 mg/m³
0.3 mg/m³

Talc (non-asbestiform)
ACGIH Threshold Limit Value (TWA)
2 mg/m³
Australia TWA
2.5 mg/m³
Austria OEL - MAKs
2 mg/m³
Belgium OEL - TWA
2 mg/m³
Bulgaria OEL - TWA
1.0 fiber/cm³
6.0 mg/m³
3.0 mg/m³
Czech Republic OEL - TWA
2.0 mg/m³
Denmark OEL - TWA
0.3 fiber/cm³
Finland OEL - TWA
0.5 fiber/cm³
Greece OEL - TWA
10 mg/m³
2 mg/m³
Hungary OEL - TWA
2 mg/m³
Ireland OEL - TWAs
10 mg/m³
0.8 mg/m³
Lithuania OEL - TWA
2 mg/m³
1 mg/m³
Netherlands OEL - TWA
0.25 mg/m³
OSHA - Final PELs - Table Z-3 Mineral D:

20 mppcf
Poland OEL - TWA
4.0 mg/m³
1.0 mg/m³
Portugal OEL - TWA
2 mg/m³
Romania OEL - TWA
2 mg/m³
Slovakia OEL - TWA
2 mg/m³
10 mg/m³
Slovenia OEL - TWA
2 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Analytical Method:
Analytical method available. Contact Pfizer Inc for further information.

Exposure Controls:
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:
Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:
Wear safety glasses or goggles if eye contact is possible.

Skin:
Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:
If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Capsule
Color: White
Odor: No data available.
Odor Threshold: No data available.
Molecular Formula: Mixture
Molecular Weight: Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available
Partition Coefficient: (Method, pH, Endpoint, Value)

Hard gelatin capsules
No data available

Magnesium stearate
No data available

Silicon dioxide, colloidal NF
No data available

Sodium lauryl sulfate
No data available

Talc (non-asbestiform)
No data available

Estramustine Phosphate Sodium
No data available
9. PHYSICAL AND CHEMICAL PROPERTIES

Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available
Flammability:
  Autoignition Temperature (Solid) (°C): No data available
  Flammability (Solids): No data available
  Flash Point (Liquid) (°C): No data available
  Upper Explosive Limits (Liquid) (% by Vol.): No data available
  Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
  Oxidizing Properties: No data available
  Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
  Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
  Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
General Information: The information included in this section describes the potential hazards of the individual ingredients.
Long Term: Animal studies have shown a potential to cause adverse effects on the fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on the reproductive system.
Known Clinical Effects: Clinical use of estrogens has resulted in breast changes (enlargement, tenderness, and secretion), along with effects on the genitourinary (changes in vaginal bleeding), and GI systems. Effects on the skin, eyes, and CNS have also been reported.

Acute Toxicity: (Species, Route, End Point, Dose)

Magnesium stearate
  Rat Oral LD50 > 2000 mg/kg
  Rat Inhalation LC50 > 2000 mg/m³

Sodium lauryl sulfate
  Rat Oral LD50 1288 mg/kg

Talc (non-asbestiform)
  Rat Oral LD50 > 1600 mg/kg

Estramustine Phosphate Sodium
  Rat Oral LD50 > 2000 mg/kg
  Rat Para-periosteal LD50 225mg/kg
  Rat Intraperitoneal LD50 337-550mg/kg
### 11. TOXICOLOGICAL INFORMATION

#### Acute Toxicity Comments:
A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Irritation / Sensitization: (Study Type, Species, Severity)
- **Sodium lauryl sulfate**
  - Eye Irritation: Rabbit, Moderate
  - Skin Irritation: Rabbit, Mild Moderate
  - Skin Sensitization: GPMT, Guinea Pig, Negative
  
- **Skin Sensitization - LLNA**
  - Mouse, Negative

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

<table>
<thead>
<tr>
<th>Duration</th>
<th>Species</th>
<th>Route</th>
<th>Dose</th>
<th>End Point</th>
<th>Target Organ</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Week(s)</td>
<td>Rat</td>
<td>Intrapitoneal</td>
<td>40 mg/kg/day</td>
<td>LOAEL</td>
<td>Male reproductive system, Female reproductive system</td>
</tr>
<tr>
<td>4 Week(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>100 mg/kg/day</td>
<td>LOAEL</td>
<td>Male reproductive system, Female reproductive system</td>
</tr>
<tr>
<td>6 Week(s)</td>
<td>Rat</td>
<td>Oral</td>
<td>30 mg/kg/day</td>
<td>LOAEL</td>
<td>Male reproductive system, Female reproductive system</td>
</tr>
<tr>
<td>8 Week(s)</td>
<td>Dog</td>
<td>Intravenous</td>
<td>0.1 mg/kg/day</td>
<td>LOAEL</td>
<td></td>
</tr>
<tr>
<td>6 Month(s)</td>
<td>Non-human Primate</td>
<td>Oral</td>
<td>30 mg/kg/day</td>
<td>LOAEL</td>
<td>Male reproductive system, Female reproductive system</td>
</tr>
</tbody>
</table>

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

- **Estramustine Phosphate Sodium**
  - Embryo / Fetal Development: Rat, Oral, 2 mg/kg/day, LOAEL, Fetotoxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

<table>
<thead>
<tr>
<th>Study Type, Cell Type/Organism</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacterial Mutagenicity (Ames)</td>
<td>Negative</td>
</tr>
<tr>
<td><strong>Estramustine Phosphate Sodium</strong></td>
<td></td>
</tr>
<tr>
<td>Bacterial Mutagenicity (Ames)</td>
<td><strong>Salmonella</strong>, E. coli</td>
</tr>
<tr>
<td>In Vitro Chromosome Aberration</td>
<td>Human Lymphocytes</td>
</tr>
<tr>
<td>In Vitro Micronucleus</td>
<td>Mouse Bone Marrow</td>
</tr>
</tbody>
</table>

#### Carcinogen Status:

- **Silicon dioxide, colloidal NF**
  - IARC: Group 3 (Not Classifiable)

- **Talc (non-asbestiform)**
  - IARC: Group 3 (Not Classifiable)

- **Estramustine Phosphate Sodium**
  - IARC: Estrogen use in post-menopausal women - Group 1
  - Nitrogen Mustard - Group 2A
12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Sodium lauryl sulfate
_Oncorhynchus mykiss_ (Rainbow Trout)  LC50  96 Hours  3.6 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:
D2a  very toxic materials
15. REGULATORY INFORMATION

Estramustine Phosphate Sodium

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- EU EINECS/ELINCS List: 257-735-7

Silicon dioxide, colloidal NF

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 231-545-4

Talc (non-asbestiform)

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 238-877-9

Magnesium stearate

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS/ELINCS List: 209-150-3

Hard gelatin capsules

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- EU EINECS/ELINCS List: Not Listed

Sodium lauryl sulfate

- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 6
- EU EINECS/ELINCS List: 205-788-1

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Carcinogenicity-Cat.2; H351 - Suspected of causing cancer
Reproductive toxicity-Cat.1B; H360Df - May damage the unborn child. Suspected of damaging fertility
Carcinogenic: Category 3
Toxic to Reproduction: Category 2

R40 - Limited evidence of a carcinogenic effect
R61 - May cause harm to the unborn child.
R62 - Possible risk of impaired fertility.

Data Sources:
Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision:
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 15 - Regulatory Information. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date: 23-Mar-2015
Prepared by: Product Stewardship Hazard Communication

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet